Pharvaris N.V.

20.09 USD
-0.57 (-2.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Pharvaris N.V. stock is down -3.74% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 May’s closed higher than April. 100% of analysts rate it a buy.

About Pharvaris N.V.

Pharvaris N.V. focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE) The company was incorporated in 2015 and is based in Leiden, the Netherlands.

  • Wedbush
    Thu May 9, 08:54
  • Morgan Stanley
    Mon Apr 22, 13:27